NeuroEndocrine Cancer Australia

❓Did you know that the incidence of NETs has more than doubled between the year 2000 and 2020? We ask that government funding for education and resources be allocated today, in line with Senate Inquiry recommendation 18. Please #MrMarkButler and #MrAnthonyAlbanese, Australia’s 7th most common cancer is on the rise. Implement the Senate Inquiry recommendations today. Australian Labor Party #LetsTalkaboutNETs #neuroendocrineCancer

As awareness of Neuroendocrine Cancers grow, survival rates have been increasing. With equitable funding & education of the general public and healthcare professionals, we hope to see survival rates increase even further - and reach our ultimate goal of a cure. Help us improve the lives of Neuroendocrine Cancer patients Australian Labor Party #LetsTalkAboutNETs #neuroendocrineCancer

Earlier diagnosis saves lives. The latest AIHW statistics are proof. Implementation of the Senate Inquiry recommendations will save lives Australian Labor Party Note: These statistics include an average of all neuroendocrine cancers, regardless of stage and grade. Please call our free NET Nurse line if you wish to discuss further. #LetsTalkAboutNETs #NeuroendocrineCancer

The Australian Institute of Health and Welfare have now declared Neuroendocrine Cancers to be a common cancer yet many patients are told that neuroendocrine cancers are rare. We urge the Australian government to implement Senate Inquiry recommendation 18, so that we can increase resources, promote neuroendocrine cancer education modules to healthcare professionals and save lives. Learn more about how you can advocate for NET patients by clicking here: https://lnkd.in/gdX-9tZf #LetsTalkAboutNETs #NeuroendocrineCancer #NETs #NECs Australian Labor Party

16 Australians are diagnosed with neuroendocrine cancer every single day. Mark Butler MP and #AnthonyAlbanese, we ask respectfully that your Government respond to the recent #SenateInquiry recommendations #NeuroendocrineCancer patients deserve equitable support and care. #LetsTalkAboutNETs #NeuroendocrineCancer Australian Labor Party

Many thanks to NET Patient Chris from Ballarat who meet with his local Member of Parliament Catherine King MP. Chris shared his experience of diagnosis, and the challenges and barriers NET patients face. We thank Catherine for taking the time to not only meet with Chris and learn about Neuroendocrine Cancer, but for her promise to contact Mark Butler MP for the much-anticipated response to the recent Senate Inquiry. Together, we are stronger. #LetsTalkAboutNETs #NeuroendocrineCancer Australian Labor Party

This week, MSD Australia & New Zealand united with colleagues from around the world to celebrate our commitment to patients. NeuroEndocrine Cancer Australia were proud to be invited to take part and present, reflecting on the past year and the patient-centred achievements and outcomes. This year’s theme, 'Transforming the World, Leading with Patients,' highlights the collective efforts to drive meaningful change. We must always remember that medicine is for the people, regardless of the type of illness, geographical location or socioeconomic status. #NeuroendocrineCancer #GlobalPatientDay #PatientsCantWait #LetsTalkAboutNETs

The clock is ticking. Neuroendocrine Cancer patients continue to face inequity in care while the NET community wait for a response from Government to the Senate Inquiry Recommendations. Once implemented, these recommendations will transform lives. Mark Butler MP, we call on you to implement these changes and provide fair treatment! #PatientAdvocacy #PatientSupport #EquitableCare #NeuroendocrineCancer #SenateInquiry #MarkButler Australian Labor Party

The 12th INCA Global NET Patient Advocate Summit took place in Segovia, Spain, on 9th – 10th September 2024. Over 30 representatives of INCA member organisations across the globe, together with the ENETS and NANETS leaders, as well as neuroendocrine cancer advocacy experts from UK and USA, elaborated on the achievements and future projects to improve NET awareness and access to optimal diagnostics and care, and advance patient-driven research. Meredith Cummins (pictured), CEO of Neuroendocrine Cancer Australia and Chair of the INCA Research Committee, presented the NET educational modules developed by Arterial Education. She also shared insights on our successes and the lessons learned. These modules are now available to healthcare professionals and nurses. On day 2, NECA showcased the research it is involved in and also provided information about being included in research and working with researchers and clinicians. To read more, go to: https://lnkd.in/gujNEPSe International Neuroendocrine Cancer Alliance

👏 Kudos to NeuroEndocrine Cancer Australia (NECA) for the successful advocacy campaign! Von Hippel-Lindau (VHL) patients and NeuroEndocrine Cancer Australia (NECA) celebrated across Australia in August when the only known treatment for VHL was recommended for listing as part of Australia’s Pharmaceutical Benefits Scheme (PBS). Until now access to Belzutifan for Australian patients was only available for Australians who are able to live overseas to access this treatment, or, pay AUD $12,000 per month. Through tireless advocacy and working alongside patients and stakeholders, NECA is delighted to share that by Christmas, patients across the country will be able to access Belzutifan for AUD $31.60 per month, or $7.70 if they hold a healthcare card. ☑ Read more: https://lnkd.in/dmt22V76 #LetsTalkAboutNETs #NeuroendocrineCancer